Literature DB >> 22638913

Ovarian cancer stem cells: elusive targets for chemotherapy.

Achuta Kumar Guddati1.   

Abstract

Ovarian cancer is one of the major causes of death in women with gynecologic malignancy. Most patients respond favorably to platinum therapy, but relapses are common. There is emerging evidence that a special subset of cells that is highly tumorigenic is responsible for recurrence of the disease. This subset of cells has been characterized by several groups and has been found to have the properties of cancer stem cells. They have been isolated from tumor samples obtained during surgical cytoreduction and also from the ascitic fluid of ovarian cancer patients. Currently, there are no known unique markers to define these cells, but several groups have used different approaches to purify them. Although some heterogeneity has been observed in these cells, most of them satisfy the functional definition of a stem cell. Advances in characterization of ovarian cancer stem cells are instrumental in developing therapies that specifically target them. This review describes the advances made in characterization of these cells, basis of their resistance to conventional chemotherapeutic agents and the prognostic implications of utilizing mechanisms specific to ovarian cancer stem cell for therapeutic interventions. Eliminating ovarian cancer stem cells could possibly lead to a prolongation of the disease-free survival period and hopefully a definitive cure.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22638913     DOI: 10.1007/s12032-012-0252-6

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  122 in total

1.  CD133 marks a myogenically primitive subpopulation in rhabdomyosarcoma cell lines that are relatively chemoresistant but sensitive to mutant HSV.

Authors:  Joseph G Pressey; Marilyn C Haas; Christine S Pressey; Virginia M Kelly; Jacqueline N Parker; G Yancey Gillespie; Gregory K Friedman
Journal:  Pediatr Blood Cancer       Date:  2012-03-09       Impact factor: 3.167

2.  Analysis of MLH1 and MSH2 expression in ovarian cancer before and after platinum drug-based chemotherapy.

Authors:  G Samimi; D Fink; N M Varki; A Husain; W J Hoskins; D S Alberts; S B Howell
Journal:  Clin Cancer Res       Date:  2000-04       Impact factor: 12.531

3.  Akt phosphorylation associates with LOH of PTEN and leads to chemoresistance for gastric cancer.

Authors:  Eiji Oki; Hideo Baba; Eriko Tokunaga; Toshihiko Nakamura; Naoyuki Ueda; Motonori Futatsugi; Kohjiro Mashino; Manabu Yamamoto; Masahiko Ikebe; Yoshihiro Kakeji; Yoshihiko Maehara
Journal:  Int J Cancer       Date:  2005-11-10       Impact factor: 7.396

4.  Ovarian cancer stem cell-like side populations are enriched following chemotherapy and overexpress EZH2.

Authors:  Siân Rizzo; Jenny M Hersey; Paul Mellor; Wei Dai; Alessandra Santos-Silva; Daniel Liber; Louisa Luk; Ian Titley; Craig P Carden; Garry Box; David L Hudson; Stanley B Kaye; Robert Brown
Journal:  Mol Cancer Ther       Date:  2011-01-07       Impact factor: 6.261

5.  PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients.

Authors:  Yoichi Nagata; Keng-Hsueh Lan; Xiaoyan Zhou; Ming Tan; Francisco J Esteva; Aysegul A Sahin; Kristine S Klos; Ping Li; Brett P Monia; Nina T Nguyen; Gabriel N Hortobagyi; Mien-Chie Hung; Dihua Yu
Journal:  Cancer Cell       Date:  2004-08       Impact factor: 31.743

6.  Identification of a small subpopulation of candidate leukemia-initiating cells in the side population of patients with acute myeloid leukemia.

Authors:  Bijan Moshaver; Anna van Rhenen; Angèle Kelder; Marjolein van der Pol; Monique Terwijn; Costa Bachas; August H Westra; Gert J Ossenkoppele; Sonja Zweegman; Gerrit Jan Schuurhuis
Journal:  Stem Cells       Date:  2008-12       Impact factor: 6.277

7.  Measurement of multiple drug resistance transporter activity in putative cancer stem/progenitor cells.

Authors:  Vera S Donnenberg; E Michael Meyer; Albert D Donnenberg
Journal:  Methods Mol Biol       Date:  2009

8.  Clinical significance of side population in ovarian cancer cells.

Authors:  Shinji Hosonuma; Yoichi Kobayashi; Satoshi Kojo; Haruka Wada; Ken-ichiro Seino; Kazushige Kiguchi; Bunpei Ishizuka
Journal:  Hum Cell       Date:  2011-01-07       Impact factor: 4.174

9.  Oocyte formation by mitotically active germ cells purified from ovaries of reproductive-age women.

Authors:  Yvonne A R White; Dori C Woods; Yasushi Takai; Osamu Ishihara; Hiroyuki Seki; Jonathan L Tilly
Journal:  Nat Med       Date:  2012-02-26       Impact factor: 53.440

10.  Functional and molecular characterisation of mammary side population cells.

Authors:  Azra J Alvi; Helen Clayton; Chirag Joshi; Tariq Enver; Alan Ashworth; Maria d M Vivanco; Trevor C Dale; Matthew J Smalley
Journal:  Breast Cancer Res       Date:  2002-10-14       Impact factor: 6.466

View more
  9 in total

1.  Enhancing delivery of small molecule and cell-based therapies for ovarian cancer using advanced delivery strategies.

Authors:  Joanne O'Dwyer; Roisin E O'Cearbhaill; Robert Wylie; Saoirse O'Mahony; Michael O'Dwyer; Garry P Duffy; Eimear B Dolan
Journal:  Adv Ther (Weinh)       Date:  2020-08-16

2.  Synergistic effects of the sesquiterpene lactone, EPD, with cisplatin and paclitaxel in ovarian cancer cells.

Authors:  Caroline van Haaften; Arnoud Boot; Willem E Corver; Jaap D H van Eendenburg; Baptist J M Z Trimbos; Tom van Wezel
Journal:  J Exp Clin Cancer Res       Date:  2015-04-25

3.  CD44+ gastric cancer cells with stemness properties are chemoradioresistant and highly invasive.

Authors:  Mao Sun; Wei Zhou; Yun-Yun Zhang; Dong-Lin Wang; Xiao-Ling Wu
Journal:  Oncol Lett       Date:  2013-03-26       Impact factor: 2.967

4.  Shikonin-loaded antibody-armed nanoparticles for targeted therapy of ovarian cancer.

Authors:  Efthymia-Iliana Matthaiou; Jaleh Barar; Raphael Sandaltzopoulos; Chunsheng Li; George Coukos; Yadollah Omidi
Journal:  Int J Nanomedicine       Date:  2014-04-15

5.  Exosomes as mediators of platinum resistance in ovarian cancer.

Authors:  Jennifer Crow; Safinur Atay; Samagya Banskota; Brittany Artale; Sarah Schmitt; Andrew K Godwin
Journal:  Oncotarget       Date:  2017-02-14

6.  TEM1-targeting PEGylated PLGA shikonin nanoformulation for immunomodulation and eradication of ovarian cancer.

Authors:  Efthymia-Iliana Matthaiou; Yi Guo; Jaleh Barar; Raphael Sandaltzopoulos; Lana E Kandalaft; Chunsheng Li; George Coukos; Yadollah Omidi
Journal:  Bioimpacts       Date:  2021-12-19

Review 7.  Ovarian cancer stem cells: a new target for cancer therapy.

Authors:  Qinglei Zhan; Chunmei Wang; Saiming Ngai
Journal:  Biomed Res Int       Date:  2013-01-30       Impact factor: 3.411

8.  Ets-1 regulates intracellular glutathione levels: key target for resistant ovarian cancer.

Authors:  Meghan L Verschoor; Gurmit Singh
Journal:  Mol Cancer       Date:  2013-11-15       Impact factor: 27.401

9.  TIMP-2 regulates proliferation, invasion and STAT3-mediated cancer stem cell-dependent chemoresistance in ovarian cancer cells.

Authors:  Ruth M Escalona; Maree Bilandzic; Patrick Western; Elif Kadife; George Kannourakis; Jock K Findlay; Nuzhat Ahmed
Journal:  BMC Cancer       Date:  2020-10-06       Impact factor: 4.430

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.